Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY-CoV016, Etesevimab
LY3832479 · 2 trials · 1 indication
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time 0 to tlast (AUC\[0-tlast\]) of LY3832479.
PK: Maximum Serum Concentration (Cmax) of LY3832479.
The number of participants with 1 or more SAEs assessed as related to the study drug and is summarized cumulatively. A serious adverse event is defined as an event that results in death, initial or prolonged hospitalization, is life-threatening, leads to persistent or significant disability/incapacity, is associated with congenital anomaly/birth defect, or is considered significant by the investigator for any other reason. A summary of all SAE's, regardless of causality, is located in the Reported Adverse Events section.
| Arm | Type | Description |
|---|---|---|
| LY3832479 | EXPERIMENTAL | Participants received single subcutaneous dose of 350 milligrams (mg) and 1000 mg LY3832479. |
| Placebo | PLACEBO_COMPARATOR | Participants received single subcutaneous dose of Placebo. |
| Name | Type | Description |
|---|---|---|
| LY3832479 | DRUG | Administered subcutaneously |
| Placebo | DRUG | Administered subcutaneously |
Inclusion Criteria: * Are overtly healthy as determined by medical evaluation including medical history and physical examination * Are willing to follow study procedures, including having nasal or nasopharyngeal swabs collected * Have a body mass index (BMI) within the range of greater than or equa...
Top 9 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | ibuzatrelvir, Nirmatrelvir/ ritonavir, BNT162b2/RIV |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Molnupiravir |
| Invivyd, Inc. | IVVD | 2 | PHASE3 | VYD2311 |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE3 | Tradipitant |
| Moderna, Inc. | MRNA | 2 | PHASE2 | mRNA-1283, mRNA-1273 |
| ImmunityBio Inc | IBRX | 2 | PHASE2 | Nogapendekin alfa inbakicept |
| Traws Pharma, Inc. | TRAW | 1 | PHASE2 | Ratutrelvir |
| GeoVax Labs, Inc. | GOVX | 1 | PHASE2 | GEO-CM04S1 |
| Gilead Sciences, Inc. | GILD | 1 | PHASE2 | Remdesivir |
LY3832479 is an investigational small molecule developed by Eli Lilly and Company for COVID-19. It has been studied in Phase 1 clinical trials involving healthy participants. The drug is not approved and remains in clinical development.
LY3832479 is being developed for the treatment of COVID-19. Its clinical program has focused on Phase 1 studies in healthy volunteers, and it has not yet been evaluated in later-stage trials for efficacy in patients with the disease.
LY3832479 is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the clinical trials evaluating the drug.
LY3832479 is in Phase 1 clinical development. Two Phase 1 trials have been completed, and no active trials are currently listed. The drug has not been approved by the FDA and remains investigational.
LY3832479 has been studied in two completed Phase 1 trials: NCT04611789, which enrolled 18 healthy participants, and NCT04441931, which enrolled 26 healthy participants. Both were conducted in the United States and are now completed.
Yes, LY3832479 is also known as LY-CoV016. The two names refer to the same investigational drug developed by Eli Lilly and Company for COVID-19, and both appear in the titles of its Phase 1 clinical trials.